Inhaled Corticosteroids and Mast Cell Stabilizers

Introduction / Overview

Inhaled corticosteroids (ICS) and mast cell stabilizers (MCS) constitute two pivotal pharmacologic groups employed in the management of airway inflammatory disorders. The former are potent anti‑inflammatory agents that act primarily through modulation of gene transcription, whereas the latter inhibit mast cell degranulation and the release of vasoactive mediators. Together, these agents address a broad spectrum of clinical conditions ranging from asthma and chronic obstructive pulmonary disease (COPD) to allergic rhinitis and nasal polyposis. Their widespread utilization underscores the importance of a comprehensive understanding of their pharmacologic profiles for both medical and pharmacy students.

Learning Objectives

• Describe the classification and chemical structures of inhaled corticosteroids and mast cell stabilizers.
• Explain the pharmacodynamic mechanisms underlying their therapeutic effects.
• Summarize key pharmacokinetic properties, including absorption, distribution, metabolism, and excretion.
• Identify approved clinical indications and common off‑label uses.
• Recognize adverse effect profiles and potential drug interactions.
• Apply knowledge of special patient populations to optimise therapeutic regimens.

Classification

Inhaled Corticosteroids

ICS are classified according to their chemical scaffold, potency, and pharmacokinetic attributes. The core structure is a glucocorticoid backbone derived from cortisol, modified by esterification and halogenation to enhance pulmonary deposition and reduce systemic absorption.

• Fluticasone propionate – highly lipophilic, potent anti‑inflammatory activity.
• Budesonide – moderate potency, balanced systemic exposure.
• Beclomethasone dipropionate – prodrug converted to beclomethasone; moderate potency.
• Mometasone furoate – long‑acting, high potency, low systemic bioavailability.
• Ciclesonide – prodrug activated by esterases; minimal systemic absorption.
• Other agents – triamcinolone acetonide, fluticasone furoate, and newer formulations such as mometasone furoate inhalation solutions.

Mast Cell Stabilizers

Commonly used MCS are sodium salts of sulfonic acids derived from natural or synthetic compounds that inhibit mast cell degranulation. They are typically administered via inhalation or topical routes for respiratory or cutaneous indications.

• Cromolyn sodium – the prototypical agent; available as inhalation powder, nebulized solution, and topical formulations.
• Nedocromil – structurally related to cromolyn; available as nebulized solution and ophthalmic drops.
• Other agents – sodium cromoglicate, sodium cromoglycate, and novel formulations such as aerosolized cromolyn for severe asthma.

Mechanism of Action

Inhaled Corticosteroids

ICS exert anti‑inflammatory effects through a series of intracellular events:

• Binding to cytoplasmic glucocorticoid receptors (GRs) with high affinity.
• Formation of a receptor‑ligand complex that translocates to the nucleus.
• Interaction with glucocorticoid response elements (GREs) on DNA, leading to transcriptional activation of anti‑inflammatory genes (e.g., lipocortin‑1, annexin‑1) and repression of pro‑inflammatory genes (e.g., cytokines, chemokines).
• Suppression of NF‑κB and AP‑1 pathways, reducing the expression of inflammatory mediators such as IL‑4, IL‑5, IL‑13, and tumor necrosis factor‑α.
• Decreased recruitment and activation of eosinophils, neutrophils, and T lymphocytes within the airway mucosa.
• Stabilization of airway smooth muscle tone and reduction of mucus hypersecretion.

These actions culminate in reduced airway hyperresponsiveness, improved lung function, and decreased frequency of exacerbations.

Mast Cell Stabilizers

The principal pharmacologic effect of MCS is the inhibition of mast cell degranulation. Mechanisms include:

• Prevention of calcium influx into mast cells, which is essential for the exocytosis of granules containing histamine, leukotrienes, and proteases.
• Stabilization of the mast cell membrane, reducing the probability of spontaneous degranulation.
• Inhibition of phospholipase A2 activity, thereby limiting arachidonic acid release and downstream leukotriene synthesis.
• Reduction of intracellular cyclic adenosine monophosphate (cAMP) degradation, contributing to anti‑inflammatory signaling.

By curtailing the release of vasoactive mediators, MCS diminish bronchoconstriction, edema, and the recruitment of inflammatory cells.

Pharmacokinetics

Absorption

ICS are formulated to deposit in the upper and lower airways. Local absorption occurs via the airway epithelium, with a small fraction entering systemic circulation. The extent of systemic absorption depends on particle size, lipophilicity, and the presence of chemical modifications that reduce pulmonary permeability.

MCS, administered as inhaled powders or nebulized solutions, also undergo local absorption. Their systemic uptake is minimal due to low lipophilicity and rapid first‑pass metabolism.

Distribution

ICS exhibit high affinity for plasma proteins, predominantly albumin and alpha‑1 acid glycoprotein. This binding limits the free fraction available for systemic action. MCS are largely confined to the respiratory tract, with negligible systemic distribution.

Metabolism

ICS are primarily metabolized in the liver via cytochrome P450 enzymes, especially CYP3A4 and CYP1A2. The metabolites are typically inactive or possess lower potency. Prodrugs such as beclomethasone dipropionate and ciclesonide are hydrolysed by esterases to release active corticosteroids.

MCS are metabolised by esterases and conjugation to glucuronic acid or sulfate groups. The metabolites are excreted unchanged or as conjugates.

Excretion

ICS metabolites are eliminated via the kidneys, with a small fraction excreted unchanged. Renal clearance is influenced by hepatic metabolism and plasma protein binding.

MCS and their metabolites are primarily excreted renally. The rate of excretion is dose‑dependent and may be altered in renal impairment.

Half‑Life and Dosing Considerations

The terminal half‑life of most inhaled corticosteroids ranges from 1.5 to 6 hours, although the duration of pharmacologic effect often exceeds the plasma half‑life due to sustained receptor engagement. Dosing intervals are typically once or twice daily, tailored to potency and patient adherence.

Mast cell stabilizers have a relatively short systemic half‑life (minutes to hours), but their local effect persists due to sustained membrane stabilization. Frequency of administration is usually 2–4 times daily, depending on the formulation and indication.

Therapeutic Uses / Clinical Applications

Approved Indications

ICS are indicated for:

• Maintenance treatment of asthma in children and adults.
• Maintenance therapy for COPD exacerbation prevention, particularly in combination with long‑acting bronchodilators.
• Allergic rhinitis and chronic rhinosinusitis with nasal polyps.
• Bronchial asthma prophylaxis in patients with exercise‑induced bronchospasm.

MCS are approved for:

• Prophylaxis of acute asthma attacks when administered before exposure to known triggers.
• Management of allergic rhinitis and chronic urticaria as topical agents.
• Pre‑procedure prophylaxis for patients with known mast cell activation disorders.

Common Off‑Label Uses

ICS are frequently employed off‑label for:

• Severe asthma not responsive to standard doses, often in combination with biologic agents.
• Bronchiectasis to reduce airway inflammation.
• Pulmonary fibrosis, as part of multi‑modal therapy.

MCS are utilized off‑label in situations such as:

• Prevention of exercise‑induced bronchospasm in elite athletes.
• Treatment of chronic cough associated with airway hyperresponsiveness.
• Adjunctive therapy for drug‑induced immediate hypersensitivity reactions.

Adverse Effects

Inhaled Corticosteroids

Common local adverse events include:

• Oral candidiasis (thrush) due to local immunosuppression.
• Dysphonia or hoarseness from laryngeal irritation.
• Hoarseness or cough exacerbated by poor inhalation technique.

Systemic adverse effects may occur with high cumulative doses:

• HPA axis suppression, manifesting as reduced cortisol production.
• Growth suppression in pediatric patients, particularly with long‑term therapy.
• Ocular hypertension and cataract formation with prolonged high‑dose use.
• Bone mineral density reduction and increased fracture risk.
• Potential increased susceptibility to infections, including tuberculosis.

Mast Cell Stabilizers

Adverse events are generally mild and include:

• Local throat irritation or cough with inhaled formulations.
• Gastro‑intestinal discomfort when administered orally or nebulized.
• Rare systemic reactions such as hypotension or tachycardia in high doses.

Black box warnings are not applicable to either class, though caution is advised in patients with known hypersensitivity to the specific agent.

Drug Interactions

Inhaled Corticosteroids

ICS may interact with drugs that alter CYP3A4 activity:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase systemic exposure, heightening the risk of adrenal suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce systemic levels, potentially decreasing efficacy.

Concomitant use of systemic corticosteroids can produce additive immunosuppressive effects, increasing infection risk. Theophylline may reduce the clearance of certain inhaled steroids, leading to higher plasma concentrations.

Mast Cell Stabilizers

Drug interactions are infrequent; however, caution is warranted when used alongside:

• High‑dose local anesthetics, which may potentiate local irritation or systemic absorption.
• Other topical anti‑inflammatory agents, such as intranasal steroids, due to additive mucosal effects.

Clinicians are advised to review each patient’s medication list to avoid inadvertent additive effects.

Special Considerations

Pregnancy and Lactation

ICS are classified as category C or D depending on the specific agent. The potential for fetal exposure is limited by low systemic absorption, yet caution is warranted. MCS are generally considered safe, but evidence is limited. Lactation may expose infants to low quantities of systemic steroids; monitoring for growth suppression is prudent.

Pediatric Considerations

In children, growth suppression is a significant concern. Dose titration and monitoring of height velocity are recommended. MCS are well tolerated in pediatric populations, with minimal systemic absorption.

Geriatric Considerations

Older adults may exhibit increased sensitivity to systemic side effects such as osteoporosis and adrenal suppression. Dose reduction and co‑prescription of calcium and vitamin D may mitigate these risks.

Renal and Hepatic Impairment

ICS metabolism is predominantly hepatic; severe hepatic impairment may necessitate dose adjustment. MCS are renally cleared; impaired renal function can lead to accumulation, though systemic toxicity remains uncommon.

Summary / Key Points

• ICS are potent anti‑inflammatory agents that act via glucocorticoid receptor modulation; MCS inhibit mast cell degranulation, stabilizing the airway.
• Both drug classes exhibit minimal systemic absorption when delivered via inhalation, but high cumulative doses can lead to systemic adverse effects.
• ICS are first‑line agents for asthma and COPD maintenance; MCS serve primarily as prophylactic agents for acute asthma and allergic conditions.
• Adverse effect profiles differ: local candidiasis and dysphonia are common with ICS, whereas local irritation predominates with MCS.
• Drug interactions should be considered, especially with CYP3A4 modulators for inhaled steroids.
• Special populations—pregnancy, pediatrics, geriatrics, and patients with renal or hepatic impairment—require tailored dosing and vigilant monitoring.
• Clinical pearls: proper inhaler technique is essential to maximise local deposition and minimise systemic exposure; rinsing the mouth after inhalation reduces the risk of thrush.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.